.svg?iar=0&updated=20230109065058&hash=B8F025B8AA9A24E727DBB30EAED272C8){kind=logo}
Resources
A wide range of informative monographs, booklets and newsletters; all developed in-house by Cipla.
View allHey there! Welcome!
Get updated on
Select Speciality
Key Trials
Better Efficacy to Safety Ratio with Fluticasone Propionate than Beclomethasone Dipropionate and Budesonide in Asthma
The efficacy of fluticasone propionate (FP) at half the dose or less was superior to budesonide (Bud) and equivalent to beclomethasone dipropionate (BDP) in improving the peak expiratory flow rate and was associated with a reduction in cortisol suppression as compared to Bud and no greater degree of cortisol suppression as compared to BDP. The efficacy to safety ratio with FP was better than Bud and BDP in the management of asthma across all severities.
Slide Library
Update on Role of Bilastine and Montelukast in Allergic Rhinitis Management
Recently an expert opinion published in the Journal of Association of Chest Physicians titled as ‘Expert opinion on the role of bilastine and bilastine-montelukast combination in the management of allergic rhinitis: An Indian perspective’. It stated that the synergistic combination of bilastine-montelukast therapy can have a dual action on early- and late-phase allergic reactions in AR patients. This combination is an attractive treatment option in allergic rhinitis patients with asthma.
Patient Education
View all
